BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 7002443)

  • 1. Effects of a luteinizing hormone-releasing hormone agonist on luteal function in women.
    Bergquist C; Nillius SJ; Wide L
    Contraception; 1980 Sep; 22(3):287-93. PubMed ID: 7002443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luteolysis induced by a luteinizing hormone-releasing hormone agonist is prevented by human chorionic gonadotropin.
    Bergquist C; Nillius SJ; Wide L
    Contraception; 1980 Oct; 22(4):341-7. PubMed ID: 7004772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early follicular phase luteinizing hormone-releasing hormone agonist administration - effects on follicular maturation and corpus luteum function in women.
    Skarin G; Nillius SJ; Wide L
    Contraception; 1982 Jan; 25(1):31-9. PubMed ID: 6800690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue--a new approach to birth control?
    Nillius SJ; Bergquist C; Wide L
    Contraception; 1978 Jun; 17(6):537-45. PubMed ID: 352612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men.
    Nillius SJ; Bergquist C; Wide L
    Int J Fertil; 1980; 25(3):239-46. PubMed ID: 6108935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated dissolution of luteal-endometrial integrity by the administration of antagonists of gonadotropin-releasing hormone and progesterone to late-luteal phase women.
    Roseff SJ; Kettel LM; Rivier J; Burger HG; Baulieu E; Yen SS
    Fertil Steril; 1990 Nov; 54(5):805-10. PubMed ID: 2226914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The sequence of pituitary responses to synthetic luteinizing hormone releasing hormone (LH-RH) throughout the normal menstrual cycle.
    Grimes EM; Thompson IE; Taymor ML
    Acta Endocrinol (Copenh); 1975 Aug; 79(4):625-34. PubMed ID: 1098349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of ovulation in women by intranasal treatment with a luteinizing hormone-releasing hormone agonist.
    Bergquist C; Nillius SJ; Wide L
    Contraception; 1979 May; 19(5):497-506. PubMed ID: 380892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure to induce early abortion by huge doses of a superactive LRH agonist in women.
    Skarin G; Nillius SJ; Wide L
    Contraception; 1982 Nov; 26(5):457-63. PubMed ID: 6819111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
    Garzo VG; Liu J; Ulmann A; Baulieu E; Yen SS
    J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of postovulatory treatment with a luteinizing hormone-releasing hormone analog on the plasma level of progesterone in women.
    Koyama T; Ohkura T; Kumasaka T; Saito M
    Fertil Steril; 1978 Nov; 30(5):549-52. PubMed ID: 363461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical observations on LRH-A used for contraception by luteolysis in normal women--analysis of 88 cases].
    Lu RK; Chen HY; Liu Y; Zhang L; He YJ; Ge LJ; Yuan XW; Qui XD
    Shengzhi Yu Biyun; 1987; 7(1):39-40, 45-7. PubMed ID: 12341309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of luteolysis by luteinizing hormone-releasing factor (LRF) agonist: sensitivity, reproducibility, and reversibility.
    Sheehan KL; Casper RF; Yen SS
    Fertil Steril; 1982 Feb; 37(2):209-12. PubMed ID: 7037463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial patterns in women on chronic luteinizing hormone-releasing hormone agonist treatment for contraception.
    Bergquist C; Nillius SJ; Wide L; Lindgren A
    Fertil Steril; 1981 Sep; 36(3):339-42. PubMed ID: 6793403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The induction of premature luteolysis in normal women--follicular phase luteinizing hormone secretion and corpus luteum function in the subsequent cycle.
    Soules MR; Bremner WJ; Dahl KD; Rivier JE; Vale WW; Clifton DK
    Am J Obstet Gynecol; 1991 Apr; 164(4):989-94; discussion 994-6. PubMed ID: 2014851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic effects of the stimulatory luteinizing hormone-releasing hormone analogue D-Ser (TBU) 6-EA 10-LRH on the gonadotrophin and gonadal steroid secretion in women with amenorrhoea.
    Skarin G; Nillius SJ; Wide L
    Ups J Med Sci; 1980; 85(2):103-12. PubMed ID: 6787767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of corpus luteum function by the gonadotropin-releasing hormone antagonist Nal-Glu: effect of the dose and timing of human chorionic gonadotropin administration.
    Dubourdieu S; Charbonnel B; Massai MR; Marraoui J; Spitz I; Bouchard P
    Fertil Steril; 1991 Sep; 56(3):440-5. PubMed ID: 1894021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical study on LRH-A contraception by luteolysis].
    Lu RK
    Zhonghua Fu Chan Ke Za Zhi; 1989 Jan; 24(1):26-8, 58. PubMed ID: 2667912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal LHRH agonist (Buserelin) after ovulation: a post-coital contraceptive approach.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Contracept Deliv Syst; 1983 Apr; 4(2):107-25. PubMed ID: 12338631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue - a new approach to birth control?
    Nillius SJ; Bergquist C; Wide L
    Contraception; 1978 Jun; 17(6):537-44. PubMed ID: 363344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.